BLFS BioLife Solutions
- 22.990
- +0.560+2.50%
BioLife Solutions News
Analysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC) and BioLife Solutions (BLFS)
BioLife Solutions Shares Are Trading Higher After Benchmark Ugpraded the Stock From Hold to Buy and Announced a $25 Price Target.
BioLife Solutions Shares Are Trading Higher After Benchmark Ugpraded the Stock From Hold to Buy and Announced a $25 Price Target.
Correction to BioLife Solutions Ratings
"BioLife Solutions Raised to Buy From Neutral by Benchmark" at 7:31 a.m. ET incorrectly stated that BioLife Solutions was raised to buy from Neutral. It was raised to buy from hold.
BioLife Solutions Raised to Buy From Neutral by Benchmark
BioLife Solutions Raised to Buy From Neutral by Benchmark
BioLife Solns Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 30.21% Benchmark → $25 Upgrades Neutral → Buy 04/04/2024 14.58% Jefferies → $22 Initiates Cover
Benchmark Upgrades BioLife Solutions to Buy From Hold With $25 Price Target
BioLife Solutions (BLFS) has an average buy rating and a price target range of $20 to $30, according to analysts polled by Capital IQ.
Several BioLife Solutions Insiders Sell Shares Sending Potential Negative Signal
BioLife Solutions, Inc. (NASDAQ:BLFS) shareholders may have reason to be concerned, as several insiders sold their shares over the past year. When evaluating insider transactions, knowing whether in
BioLife Solutions | 10-Q: Quarterly report
BioLife Solutions, Inc. (NASDAQ:BLFS) Q1 2024 Earnings Call Transcript
Lake Street Reaffirms Their Buy Rating on BioLife Solutions (BLFS)
Analysts Conflicted on These Healthcare Names: BioNTech SE (BNTX), Xenon (XENE) and BioLife Solutions (BLFS)
BioLife Solutions, Inc. (BLFS) Q1 2024 Earnings Call Transcript
BioLife Solutions, Inc. (BLFS) Q1 2024 Earnings Call Transcript
BioLife Solns (BLFS.US): The 2024 Q1 financial report achieved revenue of US$31.727 million, with a previous value of US$37.703 million, with an expected value of US$26.01 million; earnings per share of -0.20 USD, previous value of -0.27 USD, and expected
BioLife Solns (BLFS.US): The 2024 Q1 financial report achieved revenue of US$31.727 million, with a previous value of US$37.703 million, with an expected value of US$26.01 million; earnings per share of -0.20 USD, previous value of -0.27 USD, and expected value of -0.28 USD.
Earnings Flash (BLFS) BIOLIFE SOLUTIONS Posts Q1 Revenue $31.7M, Vs. Street Est of $24.9M
04:18 PM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (BLFS) BIOLIFE SOLUTIONS Posts Q1 Revenue $31.7M, vs. Street Est of $24.9M
BioLife Solutions Reiterates Guidance
2024 Revenue GuidanceBioLife Solutions is affirming its 2024 revenue guidance of $95.5 million to $100.0 million. This is based on expectations for BioLife's Cell Processing and Biostorage Services pl
BioLife Solns Q1 2024 GAAP EPS $(0.22) Beats $(0.28) Estimate, Sales $16.20M Miss $26.01M Estimate
BioLife Solns (NASDAQ:BLFS) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.28) by 21.43 percent. The company reported quarterly sales of $16.20 millio
BioLife Solutions 1Q Loss $10.2M >BLFS
BioLife Solutions 1Q Loss $10.2M >BLFS
Press Release: BioLife Solutions Reports First Quarter 2024 Financial Results
BioLife Solutions Reports First Quarter 2024 Financial Results PR Newswire BOTHELL, Wash., May 9, 2024 Cell Processing revenue increased 10% sequentially to $16.2 million GAAP gross margin of 38%
BioLife Solutions (BLFS) Receives a Buy From Craig-Hallum
BioLife Solutions to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
BOTHELL, Wash., April 30, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") an
Analysis
Price Target
No Data
